The relationship between knowledge, attitudes, and practices of community pharmacists regarding persons with substance use disorders

References

• Administration SAaMHS. Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2018.
   Google Scholar
• van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug Alcohol Depend. 2013;131(1–2):23–35.
   PubMed Web of Science ®Google Scholar
• Luoma JB, Twohig MP, Waltz T, et al. An investigation of stigma in individuals receiving treatment for substance abuse. Addict Behav. 2007;32(7):1331–1346.
   PubMed Web of Science ®Google Scholar
• Matheson C, Thiruvothiyur M, Robertson H, Bond C. Community pharmacy services for people with drug problems over two decades in Scotland: implications for future development. Int J Drug Pol. 2016;27:105–112.
   PubMed Web of Science ®Google Scholar
• Dole EJ, Tommasello A. Recommendations for implementing effective substance abuse education in pharmacy practice. Subst Abus. 2002;23(3 Suppl):263–271.
   PubMedGoogle Scholar
• Tomko JR, Giannetti VJ. Pharmacist influence in buprenorphine treatment outcomes for opioid dependence. Ann Pharmacother. 2007;41(1):161–161.
   PubMed Web of Science ®Google Scholar
• Fleming GF, McElnay JC, Hughes CM, Sheridan J, Strang J. The role of the community pharmacist in drug abuse: a comparison of service provision between Northern Ireland and England/Wales. Pharm World Sci. 2001;23(1):13–16.
   PubMedGoogle Scholar
• Green TC, Case P, Fiske H, et al. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. J Am Pharm Assoc. 2017;57(2S):S19–S27.e14.
   Google Scholar
• Joranson DE, Gilson AM. Pharmacists' knowledge of and attitudes toward opioid pain medications in relation to federal and state policies. J Am Pharm Assoc. 2001;41(2):213–220.
   Google Scholar
• Nielsen S, Menon N, Larney S, Farrell M, Degenhardt L. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. Addiction. 2016;111(12):2177–2186.
   PubMed Web of Science ®Google Scholar
• Luoma JB, O'Hair AK, Kohlenberg BS, Hayes SC, Fletcher L. The development and psychometric properties of a new measure of perceived stigma toward substance users. Subst Use Misuse. 2010;45(1–2):47–57.
   PubMed Web of Science ®Google Scholar
• Drugs for opiod use disorder. Med Lett. 2017;59(1522):89–96. https://secure.medicalletter.org/w1522a
   Google Scholar
• Ryle K. Watch for these red flags when prescribing or dispensing controlled substances. 2015. http://www.wolterskluwercdi.com/blog/watch-these-red-flags-when-prescribing-or-dispensing-controlled-substances/. Accessed July 24, 2017.
   Google Scholar
• Jones L, Edge J, Love AC. The effect of educational intervention on pharmacists' attitudes to substance misusers. J Subst Use. 2005;10(5):285–292.
   Google Scholar
• Walters C, Raymont A, Galea S, Wheeler A. Evaluation of online training for the provision of opioid substitution treatment by community pharmacists in New Zealand. Drug Alcohol Rev. 2012;31(7):903–910.
   PubMed Web of Science ®Google Scholar
• Tomko JR, Giannetti VJ. Knowledge, attitudes, and professional practices versus personal beliefs of pharmacists regarding chemically dependent patients. Ment Health Clin. 2013;3(6):302–308.
   Google Scholar
• Mackridge AJ, Scott J. Experiences, attitudes and training needs of pharmacy support staff providing services to drug users in Great Britain: a qualitative study. J Subst Use. 2009;14(6):375–384.
   Web of Science ®Google Scholar
• Waterfield J. Is pharmacy a knowledge-based profession? Am J Pharm Educ. 2010;74(3):50.
   PubMed Web of Science ®Google Scholar
• Rosenthal MM, Breault RR, Austin Z, Tsuyuki RT. Pharmacists' self-perception of their professional role: insights into community pharmacy culture. J Am Pharm Assoc. 2011;51(3):363–368.
   Google Scholar
• Christensen DB, Farris KB. Pharmaceutical care in community pharmacies: practice and research in the US. Ann Pharmacother. 2006;40(7–8):1400–1406.
   PubMed Web of Science ®Google Scholar
• Laird A, Hunter C, Sardar CM, Fitzgerald NM, Lowrie R. Community pharmacy-based opiate substitution treatment and related health services: a study of 508 patients and 111 pharmacies. J Public Health. 2016;24(3):193–207.
   Google Scholar
• Weaver KK. Collaborative practice agreements: explaining the basics. Pharm Today. 2018;24(3):55.
   Google Scholar
• Goodin A, Fallin-Bennett A, Green T, Freeman PR. Pharmacists' role in harm reduction: a survey assessment of Kentucky community pharmacists' willingness to participate in syringe/needle exchange. Harm Reduct J. 2018;15(1):4.
   PubMedGoogle Scholar
• Link BG, Struening EL, Rahav M, Phelan JC, Nuttbrock L. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. J Health Soc Behav. 1997;38(2):177–190.
   PubMed Web of Science ®Google Scholar
• Tommasello AC. Substance abuse and pharmacy practice: what the community pharmacist needs to know about drug abuse and dependence. Harm Reduct J. 2004;1(1):3–3.
   PubMedGoogle Scholar
• Horsfield E, Sheridan J, Anderson C. What do community pharmacists think about undertaking screening and brief interventions with problem drinkers? Results of a qualitative study in New Zealand and England. Int J Pharm Pract. 2011;19(3):192–200.
   PubMedGoogle Scholar
• Luty J, Kumar P, Stagias K. Stigmatised attitudes in independent pharmacies associated with discrimination towards individuals with opioid dependence. Psychiatrist. 2010;34(12):511–514.
   Google Scholar
• O'Reilly CL, Bell JS, Kelly PJ, Chen TF. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Res Social Administ Pharm. 2015;11(3):e101–e109.
   PubMed Web of Science ®Google Scholar
• Strand MA, Eukel H, Burck S. Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk. Res Social Adm Pharm. 2019;15(8):1032–1036.
   PubMed Web of Science ®Google Scholar
• Giannetti V, Caley CF, Kamal KM, et al. Community pharmacists and mental illness: a survey of service provision, stigma, attitudes and beliefs. Int J Clin Pharm. 2018;40(5):1096–1105.
   PubMed Web of Science ®Google Scholar
• Schommer JC, Sogol EM, Brown LM. Career pathways for pharmacists. J Am Pharm Assoc. 2007;47(5):563–564.
   Google Scholar